Rating of The Day: Aclaris Therap (ACRS) Hit With Outperform Rating At Leerink Swann, Firm Sees $54.00 Stock Price

November 29, 2016 - By Dolores Ford

Rating of The Day: Aclaris Therap (ACRS) Hit With Outperform Rating At Leerink Swann, Firm Sees $54.00 Stock Price

Why Leerink Swann Gives Aclaris Therap (ACRS) $54.00 Price Target

Leerink Swann analyst began coverage on Aclaris Therap (ACRS) with a $54.00 target price and Outperform rating. The target price suggests a potential upside of 79.10% from firm’s last price.

Aclaris Therapeutics Inc (NASDAQ:ACRS) Ratings Coverage

Out of 3 analysts covering Aclaris Therap… (ACRS), 3 rate it a “Buy”, 0 “Sell”, while 0 “Hold”. This means 100% are positive. $31 is the highest target while $23 is the lowest. The $30 average target is -0.50% below today’s ($30.15) stock price. Aclaris Therap… has been the topic of 4 analyst reports since March 16, 2016 according to StockzIntelligence Inc. On Friday, September 30 the stock rating was initiated by JMP Securities with “Mkt Outperform”. Citigroup maintained Aclaris Therapeutics Inc (NASDAQ:ACRS) on Wednesday, March 16 with “Buy” rating. Jefferies maintained the shares of ACRS in a report on Friday, August 12 with “Buy” rating. The firm has “Buy” rating given on Monday, September 19 by Jefferies.

About 538,749 shares traded hands or 69.33% up from the average. Aclaris Therapeutics Inc (ACRS) has risen 28.74% since April 26, 2016 and is uptrending. It has outperformed by 23.48% the S&P500.

Analysts await Aclaris Therapeutics Inc (NASDAQ:ACRS) to report earnings on March, 22. They expect $-0.67 EPS, down 139.29% or $0.39 from last year’s $-0.28 per share. After $-0.50 actual EPS reported by Aclaris Therapeutics Inc for the previous quarter, Wall Street now forecasts 34.00% negative EPS growth.

Aclaris Therapeutics, Inc. is a clinical-stage specialty pharmaceutical company. The company has a market cap of $793.39 million. The Firm is focused on identifying, developing and commercializing differentiated drugs for the treatment of dermatological indications. It currently has negative earnings. The Company’s lead drug candidate, A-101 Topical Solution, is a high-concentration hydrogen peroxide topical solution that the Company is developing as a prescription treatment for seborrheic keratosis , a non-malignant skin tumor.

According to Zacks Investment Research, “Aclaris Therapeutics, Inc. is a specialty pharmaceutical company. The Company is focused on identifying, developing and commercializing drugs to met needs in dermatology. Its drug candidate consists of A-101, a high-concentration hydrogen peroxide topical solution which is being developed as a prescription treatment for seborrheic keratosis a common non-malignant skin tumor and A-102, a proprietary topical gel dosage form of hydrogen peroxide for the treatment of SK and common warts which are in different clinical trial. Aclaris Therapeutics, Inc. is headquartered in Malvern, Pennsylvania.”

ACRS Company Profile

Aclaris Therapeutics, Inc., incorporated on July 13, 2012, is a clinical-stage specialty pharmaceutical company. The Firm is focused on identifying, developing and commercializing differentiated drugs for the treatment of dermatological indications.

More news for Aclaris Therapeutics Inc (NASDAQ:ACRS) were recently published by: Fool.com, which released: “Why Aclaris Therapeutics, Inc. Stock Is Down Today” on November 17, 2016. Investorplace.com‘s article titled: “3 Stocks to Watch on Wednesday: Aclaris Therapeutics Inc (ACRS), Agilent …” and published on November 16, 2016 is yet another important article.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter:


Recent Market News

>